How does the UK solve the innovation puzzle?

The government should help SMEs to reward their advances with quicker mass adoption by the NHS, according to Andy Mears, Managing Director of Deltex Medical Group plc (LON:DEMG)

Companies can seek grant funding or tax breaks ranging from R&D credits to the Enterprise Investment Scheme for risk investors. The Department for International Trade has helped us at Deltex get exports going in many countries. However, the great  unmet challenge comes in getting theNational Health Service to actually adopt innovative products even when they know how good they are.

The NHS has long been committed to driving the uptake of innovative medical technologies. Academic Health Science Networks (AHSNs) and the NICE Medical Technologies Evaluation Programme (MTEP) were primarily created to help companies, especially the United Kingdom’s SMEs, who have clinically supported innovation, achieve implementation at pace and scale.

Sequential innovation ensures that each clinical generation can improve standards of care for their patients. Many solutions address the very problems that healthcare systems face: more and older patients stretching limited financial resources. Innovations that improve outcomes and shorten length of hospital stays combine to deliver reduced total healthcare costs. Theoretically, then, it’s a no-brainer, but in truth it’s really not that simple.

Deltex exemplifies the innovation versus adoption challenge. Deltex has pioneered Oesophageal Doppler Monitoring (ODM), a haemodynamic monitoring technology which enables anaesthetists to ensure that surgical patients benefit from accurate, real-time management of parameters that directly influence the outcome of the procedure. ODM reduces length of stay by halving post-operative complications which are expensive to treat and knock years off patients’ remaining lifespans. ODM saves money, it frees beds, and it improves the patient experience. It’s the definition of win-win and the independent evidence agrees.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change